Just one month into 2025, a handful of stocks have already generated some massive gains. Top 2025 performers include several ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

Unsurprisingly, Akero owes this incredible one-day gain to data from a midstage clinical trial. Akero Therapeutics is ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following ...

Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...